Drugs / RGDCRAdCOX2F
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06693986 | Dec 2024 → Oct 2028 expected | pancreatic adenocarcinoma | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGDCRAdCOX2F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06693986 ↗ |
| Known as | RGDCRAdcox2F (RGD) | “RGDCRAdcox2F (RGD) is a "local" product” NCT06693986 ↗ |
| Route | Other | “single direct tumor injection” NCT06693986 ↗ |